Skip to main content
NCBI home page
Cell Transplantation logoLink to Cell Transplantation
. 2017 Feb 1;26(2):309–317. doi: 10.3727/096368916X693554

Human Recombinant Antithrombin (ATryn®) Administration Improves Survival and Prevents Intravascular Coagulation after Intraportal Islet Transplantation in a Piglet Model

Valery Gmyr ∗,†,‡, Caroline Bonner ∗,†, Ericka Moerman ∗,†,‡, Antoine Tournoys §, Nathalie Delalleau ∗,†,‡, Audrey Quenon ∗,†, Julien Thevenet ∗,†,‡, Mikael Chetboun ∗,†,§, Julie Kerr-Conte ∗,†,‡, François Pattou ∗,†,‡,§, Thomas Hubert ∗,†,‡,§, Merce Jourdain ∗,†,‡,§
PMCID: PMC5657771  PMID: 27938471

Abstract

Human islet transplantation is a viable treatment option for type 1 diabetes mellitus (T1DM). However, pancreatic islet inflammation after transplantation induced by innate immune responses is likely to hinder graft function. This is mediated by incompatibility between islets and the blood interface, known as instant blood-mediated inflammatory reaction (IBMIR). Herein we hypothesized that portal venous administration of islet cells with human recombinant antithrombin (ATryn®), a serine protease inhibitor (serpin), which plays a central role in the physiological regulation of coagulation and exerts indirect anti-inflammatory activities, may offset coagulation abnormalities such as disseminated intravascular coagulation (DIC) and IBMIR. The current prospective, randomized experiment was conducted using an established preclinical pig model. Three groups were constituted for digested pancreatic tissue transplantation (0.15 ml/kg): control, NaCl 0.9% (n = 7); gold standard, heparin (25 UI/kg) (n = 7); and human recombinant ATryn® (500 UI/kg) (n = 7). Blood samples were collected over time (T0 to 24 h), and biochemical, coagulation, and inflammatory parameters were evaluated. In both the control and heparin groups, one animal died after a portal thrombosis, while no deaths occurred in the ATryn®-treated group. As expected, islet transplantation was associated with an increase in plasma IL-6 or TNF-α levels in all three groups. However, DIC was only observed in the control group, an effect that was suppressed after ATryn® administration. ATryn® administration increased antithrombin activity by 800%, which remained at 200% for the remaining period of the study, without any hemorrhagic complications. These studies suggest that coadministration of ATryn® and pancreatic islets via intraportal transplantation may be a valuable therapeutic approach for DIC without risk for islets and subjects.

Keywords: Antithrombin (AT), Instant blood-mediated inflammatory reaction (IBMIR), Disseminated intravascular coagulation (DIC), Piglet, Intraportal islet transplantation

Introduction

Type 1 diabetes mellitus (T1DM) is a chronic, progressive autoimmune disorder characterized by destruction of insulin-producing β-cells. The morbidity and mortality associated with T1DM are mainly related to the development of long-term microvascular and macrovascular complications1. Insulin therapy has allowed T1DM to become a chronically manageable condition2; however, concerted efforts globally have emerged to ameliorate the symptoms and complications of T1DM via restoration of β-cell mass function through islet transplantation3–5. With the constant global rise in the incidence of T1DM and a limited supply of donor pancreata from scarce organ donors, continuous efforts are being pursued to improve islet isolation procedures and prevent islet loss, especially in the immediate posttransplant period through a series of strategies6.

Intrahepatic islet infusion via the portal vein, also referred to as intraportal islet allotransplant, accounts for virtually all clinical islet transplants conducted world-wide7. However, a significant amount of intraportal islet mass is lost immediately posttransplant because of innate immune responses, thus triggering pancreatic islet inflammation, which is likely to hinder graft function. This process is mediated primarily by incompatibility between islets and the blood interface, a phenomenon known as instant blood-mediated inflammatory reaction (IBMIR)8. IBMIR has been linked to a variety of inflammatory mediators, such as binding of antibody and complement, rapid activation of the coagulation cascade, and innate cellular infiltration, all of which contribute to islet destruction and nonengraftment8,9. As a result, after transplantation, the final islet cell survival rate is approximately 20% to 40% compared to that of a healthy nondiabetic subject10. Furthermore, inflammation-induced venous thrombosis may develop. Inflammatory thrombosis is driven by tissue factor (TF) and thus manifests itself clinically with formation of thrombi with entrapped islets11,12, resulting in massive thrombosis in the portal vein and a decrease in the engraftment of islets. Despite continued procedural improvements in isolation techniques13 and strategies devised to selectively block the immune responses against the graft, insulin independence among autologous islet transplantation patients is rather poor, ranging at about 40%14. Thrombin, a serine proteinase generated from the zymogen prothrombin, is considered to be the key enzyme in the clotting reaction and therefore plays an important role in the IBMIR reaction. Indeed, studies have shown that inhibition of thrombin abrogates the IBMIR triggered by isolated human islets and reduces the adverse effects of IBMIR in clinical islet transplantation15 and therefore poses as an attractive therapy option for T1DM.

Antithrombin (AT) is a non-vitamin K-dependent protease that inhibits coagulation by lysing thrombin and Factor Xa (FXa). AT activity is also markedly potentiated by heparin and is associated with an anti-inflammatory and antiprotease activity16. It also inhibits neutrophil activation17. ATryn® (human recombinant antithrombin) is an anticoagulant manufactured by GTC Biotherapeutics (Framingham, MA, USA). It is a milk-derived biological product produced by genetically engineered (GE) goats to produce human AT18. In view of ATryn® properties, we hypothesized that portal venous administration of islet cells with ATryn®, which plays a central role in the physiological regulation of coagulation and exerts indirect anti-inflammatory activities, may offset coagulation abnormalities such as disseminated intravascular coagulation (DIC) and IBMIR observed during pancreatic islet engraftment.

Materials and Methods

Animals and Experimental Protocol

All animal procedures were performed in the Department of Experimental Research of the Lille University, Lille, France, in accordance with French regulations for animal experiments. A total of n = 28 healthy female piglets (3–4 months) weighing 26 ± 2 kg (Pannier's breeding, Wylder, France) were used for the study. Pancreases were obtained from seven donors, and three groups were constituted for the transplantation with digested pancreatic tissue (0.15 ml/kg): control using NaCl 0.9% (n = 7), heparin (25 UI/kg) (n = 7) (Sanofi, Gentilly, France), and ATryn® (500 UI/kg) (n = 7). ATryn® (a gift from GTC Biotherapeutics) powder (7 UI/mg) was dissolved in solution distilled water.

Pancreatectomy, Pancreatic Tissue Isolation, and Graft

All surgical procedures were performed under gen eral anesthesia, induced following administration of buprenorphine at 0.03 mg/mg by subcutaneous injection (nalbuphine; Merck, Paris, France), an intramuscular injection of 0.3 mg/kg of midazolam (Hypnovel®; Roche, Neuillysur-Seine, France), and 5 mg/kg of ketamine (Ketamine Virbac®; Virbac, Carros, France). Tracheal intubation was performed subsequently with 0.2 ml/kg/h of intravenous propofol (Diprivan® 1%; AstraZeneca, Rueil-Malmaison, France). In all cases, partial pancreatectomy was performed with cautious dissection to maintain normal vascularization and to minimize warm ischemia until final excision of the tail of the pancreas. The explanted pancreas was immediately cooled in Hank's solution (Sigma-Aldrich Chimie, Saint-Quentin-Fallavier, France) at 4°C.

Within 30 min of cold ischemia, the pancreas was distended by infusion of 250 mg of collagenase and neutral protease (SERVA Electrophoresis Gmbh, COGER SAS, Paris, France) using an 18-gauge catheter (Optiva®; Ethicon, Pomezia, Italy) inserted in the pancreatic duct. Pancreatic tissue was isolated using state-of-the-art techniques as previously described19. The digested pancreatic tissue was resuspended in Connaught Medical Research Laboratories medium (CMRL) (Thermo Fisher Scientific, Illkirch, France) and supplemented with porcine serum, respectively, from each recipient and transported at room temperature to the operating theater.

Blood samples were drawn by a catheter placed in the jugular vein. After each sample, the catheter was flushed with saline buffer. Pancreatic digested tissue was placed in a 60-ml syringe with ATryn® or heparin and was injected at 2 ml/min. Cell injection was performed on anesthetized animals via a catheter placed directly in the portal vein. All hemodynamic parameters were monitored during injection. After injection, animals were woken and a catheter was maintained for blood sampling.

The same conditions were used for control experiments. All studies were performed in agreement with French regulations and approved by the institutional ethics committees of Lille University.

Blood Sampling and Biological Measurements

Blood samples were collected before injection (T0) and after 30 min, 1 h, 2 h, 3 h, 6 h, 12 h, 24 h and were collected from the arterial catheter in sterile tubes, and plasma was immediately separated after centrifugation at 4,815 × g for 10 min. Leukocyte, hemoglobin, and platelet counts were obtained on ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich Chimie) anticoagulated blood. For coagulation assays, blood was collected in tubes containing 3.8% sodium citrate (Sigma-Aldrich Chimie). Prothrombin time (PT) and fibrinogen levels were rapidly measured by standard procedures. Immunoassay methods were used to determine quantitative thrombin–AT (TAT) complexes (Enzygnost TAT micro; Siemens, Munich, Germany). Fibrin monomer (Liatest FM; Diagnostica Stago, Asnieres, France) and D-dimer (Innovance DDI; Siemens, Marburg, Germany) were performed by immu-noturbidimetric assay. Quantitative AT activity was determined by chromogenic assay (Berichrom AT; Siemens). Inflammation [tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)] parameters were measured with an ELISA method (Porcine Quantikine ELISA; R&D Systems, Lille, France).

Toxicity Test

ATryn toxicity was performed in human islets (n = 3 preparations). Human pancreata were isolated from adult, brain-deceased donors in agreement with our institu tional ethical committee, and islets were isolated according to a modified version as described previously20. Purification was achieved with Biocolle (Biochrom Ltd., Cambridge, UK) continuous density gradients using a COBE 2991 cell separator (Terumo BCT, Lakewood, CO, USA)21.

Purified islets were cultured with or without ATryn® (5 UI/ml = 0.7 mg/ml) for 24 h. We reproduced our clinical protocol, and we used the culture medium CMRL with 1 g/L of glucose (Thermo Fisher Scientific, Courtaboeuf, France) with penicillin/streptomycin and human serum albumin (HSA) 0.625% (Vialebex, Les Ulis, France).

Viability (blue trypan test), percentage of recovery, percentage of insulin secretion (20 mM glucose), and apoptosis (Cell Death Detection ELISA PLUS; Roche, Boulogne-Billancourt, France) were evaluated. Each condition was performed six times, and insulin secretion was normalized to intracellular insulin content.

Statistical Analysis

All data were expressed as mean ± standard error of the mean (SEM). Statistical analyses were performed using analysis of variance (ANOVA) with Tukey's post hoc test for repeated measures during the first 24 h of the experience. Analyses were performed using StatView 6® (SAS, Cary, NC, USA), and values of p < 0.05 were considered statistically significant.

Results

Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides called glycosaminoglycans that have anticoagulant properties. Previous studies have shown that heparin in combination with AT inhibits thrombosis by inactivating activated FX and inhibiting the conversion of prothrombin to thrombin22. However, studies comparing the AT efficacy of heparin and recombinant ATryn® have not been carried out. The purpose of this investigation was to evaluate the effect of heparin versus ATryn® on the mortality rate and DIC following intraportal islet administration in piglets. Three groups were constituted for digested pancreatic tissue transplantation (0.15 ml/kg): control, NaCl 0.9% (n = 7); gold standard, heparin (25 UI/kg) (n = 7); and human recombinant ATryn® (500 UI/kg) (n = 7). In both the control and heparin groups, one animal died following intraportal islet administration at 25 and 150 min, respectively, due to a massive portal thrombosis, while no deaths occurred in the ATryn® group (Fig. 1A). The autopsy results revealed a massive portal thrombosis (Fig. 1B) that was associated with cardiogenic shock manifested by sinus tachycardia, hypotension, followed by ventricular tachycardia with ventricular fibrillation. Postoperative complications, such as hemorrhagic complication as hemoperitoneum, were absent in the animals. A low serum albumin concentration was observed in the first hours of the experiment, increasing after 2 h and stabilizing for the rest of the experiment in the heparin and ATryn® groups. However, there were no differences in hepatic response to islet injection between groups (Fig. 1C). These data suggest that intraportal islet administration could be associated with a low hemodilution, increasing at 2 h. In the ATryn® group, a rapid increase in AT activity was observed after 30 min (200% activity), which escalated to 800% activity within 3 h. After 5 h, AT activity was maintained over 200% until the end of the experiment (Fig. 1D).

Figure 1.

Figure 1.

Open in a new tab

ATryn® administration in vivo prevents death and DIC. (A) Kaplan–Meier survival curves of piglets treated with NaCl 0.9% (n = 7), heparin (25 UI/kg) (n = 7), or ATryn® (500 UI/kg) (n = 7) from time 0 to 24 h. (B) Photograph of livers after sacrifice. (C) Serum albumin (g/L) from time 0 to 24 h. (D) Plot of plasma antithrombin activity expressed as percentage of activity. Data are expressed as means ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, two-way ANOVA and Tukey's post hoc test. DIC, disseminated intravascular coagulation; SEM, standard error of the mean; ANOVA, analysis of variance.

ATryn® Functions as a Potent Anticoagulant

We next investigated the effect of ATryn® versus NaCl (placebo) and heparin (reference treatment) versus NaCl on coagulation activity by using markers of coagulation, that is, TAT complex, fibrin monomer, platelets, prothrombin, and D-dimer. We have observed an initial peak in TAT activity (2 h) in the ATryn® versus NaCl group compared to the heparin versus NaCl group. In fact, TAT activity was significantly higher in the ATryn® versus NaCl group compared to the heparin versus NaCl group (Fig. 2A). A rapid and significant increase in fibrin monomers was observed in the NaCl group compared to the heparin and ATryn® groups (Fig. 2B).

Figure 2.

Figure 2.

Open in a new tab

Levels of markers of coagulation. (A) TAT (μg/L), (B) fibrin monomer (μg/ml), (C) platelets (%), (D) prothrombin (%), and (E) D-dimer (mg/L) at baseline up to 24 h in relation to treatment with NaCl, heparin, or ATryn® in the piglet. Data are expressed as means ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, two-way ANOVA and Tukey's post hoc test. ANOVA, analysis of variance; TAT, thrombin–antithrombin; SEM, standard error of the mean.

There was no significant difference in platelet count and PT between groups at 24 h (Fig. 2C and D). There was no significant difference in platelet count between the three groups during the course of the experiment (Fig. 2C). However, there was a tendency of thrombocytopenia in the first 5 h of the experiment (Fig. 2D). D- Dimers reflecting activation of fibrinolysis were increased rapidly after islet administration in the NaCl group (Fig. 2E), achieving a maximum level at 3 h. However, this effect was lower in the ATryn® and heparin groups. ATryn® administration was associated with a significant decrease in coagulation parameters such as D-dimers and fibrin monomers compared to control.

ATryn® Does Not Modulate TNF-α and IL-6

Previous studies have shown that administration of ATryn® in human endotoxemia suppressed inflammatory markers such as TNF-α and IL-623. In this study, we did not observe any significant change in TNF-α or IL-6 levels after ATryn® administration (Fig. 3A and B). In parallel, there was no significant change in leukocyte count and fibrinogen levels across the three groups at 24 h (Fig. 3C and D).

Figure 3.

Figure 3.

Open in a new tab

Levels of markers of inflammation. (A) TNF-α (pg/ml), (B) IL-6 (pg/ml), (C) leukocyte counts (109/L), and (D) fibrinogen (g/L) at baseline up to 24 h in relation to treatment with NaCl, heparin, or ATryn® in the piglet. Data are expressed as means ± SEM. Nonsignificant (ns), two-way ANOVA and Tukey's post hoc test. SEM, standard error of the mean; ANOVA, analysis of variance; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6.

ATryn® Does Not Seem Toxic for Islets

Here we show for the first time that ATryn® treatment in human islet cultures in vitro had no effect on islet viability, recovery, or insulin secretion (Fig. 4). Thus, the mechanisms of these effects remain to be evaluated. More studies are needed to clarify if anticoagulant or anti-inflammatory effects of recombinant human AT (ATryn®) are implicated.

Figure 4.

Figure 4.

Open in a new tab

Characterization of the toxic effects of ATryn® in human islet cultures after 24 h. (A) Cell viability determined by the trypan blue exclusion test (%). (B) Islet recovery by cell counting using dithizone staining (%). (C) Insulin secretion (percentage of content) after stimulation with 20 mM glucose. (D) Apoptosis (absorbance in nanometers) determined by Cell Death Detection ELISA PLUS in the presence or absence of ATryn® (5 UI/ml = 0.7 mg/ml) in human islet cultures (n = 3 individual donors in duplicate) for 24 h. Data are expressed as means ± SEM. Nonsignificant (ns), Student's t-test. SEM, standard error of the mean.

Discussion

AT is a natural anticoagulant produced by the liver that plays a fundamental role in maintaining coagulation homeostasis by inhibiting thrombin and FXa and, to a lesser extent, FIXa and FXIa24,25. In addition to its anticoagulant function, it has also been shown to have potent anti-inflammatory and antiaggregant properties, mediated through the release of prostacyclins from endothelial cells26–28. The administration of AT seems to also be efficient to reverse the coagulation abnormalities in patients with signs of DIC29. AT derived from human plasma is therefore an essential class of therapeutics used in the treatment of life-threatening conditions resulting from trauma, infections, or sepsis. Like all other plasma derivates, AT concentrates are prepared from pools of human plasma ranging from 10,000 to 50,000 donations, which are required for industrial processing. More over, because of the human origin of the starting material, the major risk associated to plasma products is the transmission of blood-borne infectious agents30. Another source of AT replacement is human recombinant AT (ATryn®). ATryn® is produced through transgenic technology, which results in a purified AT substitute that is collected from milk of GE goats rather than from pooled human blood18.

The present study demonstrates that administration of ATryn® restored AT plasma concentrations without deleterious effects and was associated with a significant decrease in DIC. Although AT supraphysiological levels were achieved in our piglet model, we have not observed deaths nor hemorrhagic complications, while in the control (NaCl) and heparin groups we saw the death of one animal per group by portal thrombosis. This death was secondary to portal thrombosis provoked by local coagulation activation. Thus, the anticoagulant effect of ATryn® seems more robust in our piglet model. In humans, AT has been studied in severe sepsis with or without DIC31,32. A recent meta-analysis found AT to be beneficial in terms of mortality to treat patients with septic DIC, without any notable side effects33. Similar findings were reported in severe pneumonia with DIC34. In contrast, studies by Allingstrup et al.35 did not find any beneficial effect of this treatment in patients with septic DIC or in patients with sepsis alone. In our model, animals with DIC who were treated with ATryn® had improved coagulation and viability.

Islet transplantation is a well-established therapeutic treatment for a subset of patients with T1DM. However, several pancreases are required to obtain a sufficient number of islets of Langerhans to establish insulin independence. A major drawback is the massive loss of islets, which occurs within minutes following the transplant. This has been attributed to coagulation abnormalities such as IBMIR that results in profound cellular degradation15,36, but also to activation of endothelial cells with the appearance of DIC and ischemia by a lack of vascularization37. IBMIR is also accompanied by activation of coagulation with decreased fibrinolysis as reflected in the elevation of TAT38. Inhibition of thrombin activation by melagatran has already shown efficacy in the reduction of IBMIR15. Thus, treatment with ATryn® may regulate coagulation activation and inflammation, via its anti-inflammatory properties and downregulation of neutrophils39, to improve the engraftment of islets. In our model, we observed a decrease in leukocyte counts in animals treated with ATryn®; however, we were unable to demonstrate any effect on the release of TNF-α and IL-6. Our findings suggest that ATryn® administration with islets directly in the portal vein may offset the recruitment and activation of leukocytes to the site of transplantation and thus improve engraftment. We deliberately chose a high dose (500 mg/kg) of ATryn® to be administered in animals in order to obtain a more effective and adequate anti-inflammatory effect. A striking correlation between AT activity and dosing (range, 50–150 IU/kg) has been previously demonstrated40. However, the anti-inflammatory effect requires doses >250 IU/kg41. The inflammatory response associated with islets has been long recognized as the primary cause of early damage to islets and graft loss after transplantation. Here we did not observe any significant change in TNF-α or IL-6 levels after ATryn® administration. However, we observed a gradual decrease, but nonsignificant, in leukocyte activation in animals treated with ATryn® compared to the heparin-treated group. These results are consistent with the inhibition of polynuclear chemotactism by ATryn® via the regulation of syndecan-4 receptor, which is important for the regulation of inflammatory effects of platelets42.

Conclusion

In conclusion, our results suggest that coadministration of ATryn® and pancreatic islets in the portal vein improves DIC. Although the anticoagulant effect is similar to that of heparin, ATryn® administration is associated with a better survival outcome for the animals. These studies also suggest that very high doses of ATryn® are not associated with side effects such as hemorrhagic complications. They also suggest that ATryn® may be a valuable therapeutic approach for DIC without risk for islets and subjects.

Acknowledgments

The authors acknowledge Dr. Yann Echelard, GTC Biotherapeutics, Framingham, MA, USA, for providing ATryn®. This work was supported by grants from LFB Biotechnology, France. The authors declare no conflicts of interest.

References

  • 1.Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008; 88(11): 1322–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012; 367(14): 1332–40. [DOI] [PubMed] [Google Scholar]
  • 3.Vantyghem MC, Defrance F, Quintin D, Leroy C, Raverdi V, Prevost G, Caiazzo R, Kerr-Conte J, Glowacki F, Hazzan M, Noel C, Pattou F, Diamenord AS, Bresson R, Bourdelle-Hego MF, Cazaubiel M, Cordonnier M, Delefosse D, Dorey F, Fermon C, Fontaine P, Gillot C, Haye S, Le Guillou AC, Karrouz W, Lemaire C, Lepeut M, Leroy R, Mycinski B, Parent E, Siame C, Sterkers A, Torres F, Verier-Mine O, Verlet E; G4 working groups, Desailloud R, Dürrbach A, Godin M, Lalau JD, Lukas-Croisier C, Thervet E, Toupance O, Reznik Y, Westeel PF,. Treating diabetes with islet transplantation: Lessons from the past decade in Lille. Diabetes Metab. 2014; 40(2): 108–19. [DOI] [PubMed] [Google Scholar]
  • 4.Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Sotck PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, O'Connell PJ, Greenbaum C, Kudva YC, Brayman KL, Aull MJ, Larsen C, Kay TW, Fernandez LA, Vantyghem MC, Bellin M, Shapiro AM,. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care 2012; 35(7): 1436–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Vantyghem MC, Balavoine AS, Caiazzo R, Kerr-Conte J, Noel C, Pattou F,. Diabetes cell therapy: A decade later. Minerva Endocrinol. 2011; 36(1): 23–39. [PubMed] [Google Scholar]
  • 6.Emamaullee JA, Shapiro AM. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006; 55(7): 1907–14. [DOI] [PubMed] [Google Scholar]
  • 7.Vantyghem MC, Kerr-Conte J, Arnalsteen L, Sergent G, Defrance F, Gmyr V, Declerck N, Raverdy V, Vandewalle B, Pigny P, Noel C, Pattou F. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009; 32(8): 1473–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: Implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000; 105(2): 125–33. [DOI] [PubMed] [Google Scholar]
  • 9.Bennet W, Bjorkland A, Sundberg B, Davies H, Liu J, Holgersson J, Korsgren O. A comparison of fetal and adult porcine islets with regard to Gal alpha (1,3)Gal expression and the role of human immunoglobulins and complement in islet cell cytotoxicity. Transplantation 2000; 69(8): 1711–7. [DOI] [PubMed] [Google Scholar]
  • 10.Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock G, Larsen I, Shapiro AM. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50(4): 710–9. [DOI] [PubMed] [Google Scholar]
  • 11.Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, Bretzel RG, Elgue G, Larsson R, Nilsson B, Korsgren O. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48(10): 1907–14. [DOI] [PubMed] [Google Scholar]
  • 12.Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A, Felldin M, Kallen R, Salmela K, Tibell A, Tufveson G, Ekdahl KN, Elgue G, Korsgren O, Nilsson B. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54(6): 1755–62. [DOI] [PubMed] [Google Scholar]
  • 13.Balamurugan AN, Loganathan G, Bellin MD, Wilhelm JJ, Harmon J, Anazawa T, Soltani SM, Radosevich DM, Yuasa T, Tiwari M, Papas KK, McCarthy R, Sutherland DE, Hering BJ. A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. Transplantation 2012; 93(7): 693–702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Matsumoto S. Autologous islet cell transplantation to prevent surgical diabetes. J Diabetes 2011; 3(4): 328–36. [DOI] [PubMed] [Google Scholar]
  • 15.Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: Possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51(6): 1779–84. [DOI] [PubMed] [Google Scholar]
  • 16.Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: Anti-inflammatory properties and clinical applications. Thromb Haemost. 2016; 115(4): 712–28. [DOI] [PubMed] [Google Scholar]
  • 17.Rehberg S, Yamamoto Y, Sousse LE, Jonkam C, Zhu Y, Traber LD, Cox RA, Prough DS, Traber DL, Enkhbaatar P. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med. 2013; 41(12): e439–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.GTC Biotherapeutics I. ATryn prescribing information. (cited 2009. Feb 3). Available from http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplas-maproducts/ucm134045.pdf
  • 19.Hubert T, Arnalsteen L, Jany T, Prieur E, Triponez F, Nunes B, Vantyghem MC, Gmyr V, Kerr-Conte J, Proye C, Pattou F,. (Technique of pancreatic procurement for pancreatic islet isolation). Ann Chir. 2005; 130(6–7): 384–90. [DOI] [PubMed] [Google Scholar]
  • 20.Kerr-Conte J, Pattou F, Xia Y, Proye C, Lefebvre J. Simple dithizone-stained multilayer test for selection of density gradient before human islet mass purification. Transplant Proc. 1994; 26(6): 3413–5. [PubMed] [Google Scholar]
  • 21.Lake SP, Bassett PD, Larkins A, Revell J, Walczak K, Chamberlain J, Rumford GM, London NJ, Veitch PS, Bell PR, James RFL. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989;38(Suppl 1): 143–5. [DOI] [PubMed] [Google Scholar]
  • 22.Yin ET, Wessler S. Heparin-accelerated inhibition of activated factor X by its natural plasma inhibitor. Biochim Biophys Acta 1970; 201(2): 387–90. [DOI] [PubMed] [Google Scholar]
  • 23.Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther. 2006; 79(1): 23–34. [DOI] [PubMed] [Google Scholar]
  • 24.Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246(5432): 355–7. [DOI] [PubMed] [Google Scholar]
  • 25.Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973; 248(18): 6490–505. [PubMed] [Google Scholar]
  • 26.Taylor FB Jr., Emerson TE Jr., Jordan R, Chang AK, Blick KE,. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26(3): 227–35. [PubMed] [Google Scholar]
  • 27.Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol. 1999; 19(6): 1566–72. [DOI] [PubMed] [Google Scholar]
  • 28.Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10(2): 90–6. [DOI] [PubMed] [Google Scholar]
  • 29.Wiedermann CJ. Improvement in coagulation markers with antithrombin—Beneficial in severe sepsis? Crit Care Med. 2004; 32(9): 1968–9. [DOI] [PubMed] [Google Scholar]
  • 30.Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007; 21(2): 101–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation. J Intensive Care 2016; 4: 23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: A perspective from Japan. Int J Hematol. 2016; 103(3): 253–61. [DOI] [PubMed] [Google Scholar]
  • 33.Umemura Y, Yamakawa K, Kiguchi T, Yoshikawa Y, Ogura H, Shimazu T, Hamasaki T, Fujimi S. Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese association for acute medicine criteria. Clin Appl Thromb Hemost. 2016; 22(2): 153–60. [DOI] [PubMed] [Google Scholar]
  • 34.Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: An observational nationwide study. J Thromb Haemost. 2014; 12(9): 1470–9. [DOI] [PubMed] [Google Scholar]
  • 35.Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A. Antithrombin III for critically ill patients: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2016; 42(4): 505–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Naziruddin B, Iwahashi S, Kanak MA, Takita M, Itoh T, Levy MF. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant. 2014; 14(2): 428–37. [DOI] [PubMed] [Google Scholar]
  • 37.Del Toro-Arreola A, Robles-Murillo AK, Daneri-Navarro A, Rivas-Carrillo JD. The role of endothelial cells on islet function and revascularization after islet transplantation. Organogenesis 2016; 12(1): 28–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wang S, Zhao Z, Cong Z, Suo G. Thrombin-activatable fibrinolysis inhibitor is activated in an instant blood-mediated inflammatory reaction after intraportal islet transplant. Exp Clin Transplant. 2014; 12(1): 62–6. [DOI] [PubMed] [Google Scholar]
  • 39.Neviere R, Tournoys A, Mordon S, Marechal X, Song FL, Jourdain M, Fourrier F. Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001; 15(3): 220–5. [DOI] [PubMed] [Google Scholar]
  • 40.Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV Jr., Spyropoulos AC, Steiner T, Del Zoppo GJ, Eikelboom J,. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care 2016; 20(1): 115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001; 29(1): 134–9. [DOI] [PubMed] [Google Scholar]
  • 42.Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun. 2001; 287(1): 42–6. [DOI] [PubMed] [Google Scholar]

Articles from Cell Transplantation are provided here courtesy of SAGE Publications

RESOURCES